Financials
Financial year 2025
Worth noting
- More debts than assets in the latest financial year.
- A loss two years in a row.
- Little cash and receivables against the short-term debts.
Revenue
€ 0
▼ 100% vs 2024
Profit
Caution€ -13.7 million
▼ 988% vs 2024
Debts
High€ 4 million
▼ 23% vs 2024
Hirundo Biosciences from Liège, company number BE0681855065, closed financial year 2025 with a result of € -13.7 million after tax. For that financial year Hirundo Biosciences recorded revenue of € 0 and equity of € -548,240. Compared with financial year 2024, the result moved from € -1.3 million to € -13.7 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 24, 2026.
What happened at Hirundo Biosciences?
What happened at Hirundo Biosciences in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- András Kovács Lászlò stepped down as director. NBB
- Istvàn Greiner stepped down as director. NBB
- Péter Turek stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 13.7 million. Source: NBB ↗
- András Kovács Lászlò became a director. NBB
- Istvàn Greiner became a director. NBB
- Péter Turek became a director. NBB
- New establishment in Liège. KBO
In short
From € 210,811 loss in 2021 to € 13.7 million loss in 2025.
On average € 54,400 of value added per employee in 2024.
A new publication or filing at Hirundo Biosciences? We notify you, reason included.
Follow Hirundo BiosciencesNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
It owns 100% of Hirundo Biosciences France SAS itself.
Directors
According to the 2025 annual accounts
András Kovács Lászlò
Director
since 2025 · until 2030
Istvàn Greiner
Director
since 2024 · until 2030
Péter Turek
Director
since 2024 · until 2030
Establishments
Establishment units
Physical locations of this company
Boulevard de Patience et Beaujonc 3
4000 Liège
Avenue de l'Hôpital 11
4000 Liège
Active since 28 September 2017
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 23 companies are registered at this address.
Hyloris Developments
€ 5.1 million revenue · 2025
ONCORADIOMICS
€ 2.4 million gross margin · 2025
DERMAX
€ 1.6 million revenue · 2025
Hyloris
€ 384,852 revenue · 2025
Hyloris Pharmaceuticals
€ 3.8 million revenue · 2025
+18 more
Details
- Company number
- 0681.855.065
- VAT number
- BE 0681.855.065
- Registered office
- Boulevard de Patience et Beaujonc 3, 4000 Liège
- Names & denominations
- Hirundo Biosciences
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 28 September 2017
- Peppol
- Active · Active since 3 Dec 2025
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Handel in eigen onroerend goed
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied